MedTrace Logo

Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide

NCT04989140 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-08-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of ixazomib, oral dexamethasone and in patients with relapsed multiple myeloma who have received lenalidomide.

Conditions

Interventions

DRUG

Drug: Ixazomib Drug:pomalidomide Drug:dexamethasone

Treatment was continued until disease progression, unacceptable toxicity

Sponsors & Collaborators

  • Beijing Jishuitan Hospital

    collaborator OTHER

  • Beijing Chao Yang Hospital

    collaborator OTHER

  • Tianjin Medical University General Hospital

    collaborator OTHER

  • The First Affiliated Hospital of Zhengzhou University

    collaborator OTHER

  • Peking University Third Hospital

    collaborator OTHER

  • Beijing Hospital

    collaborator OTHER_GOV

  • The First Affiliated Hospital of Anhui Medical University

    collaborator OTHER

  • Second Hospital of Shanxi Medical University

    collaborator OTHER

  • The First Affiliated Hospital of Dalian Medical University

    collaborator OTHER

  • The Second Affiliated Hospital of Harbin Medical University

    collaborator OTHER

  • Tianjin Medical University Cancer Institute and Hospital

    collaborator OTHER

  • First Hospital of China Medical University

    collaborator OTHER

  • Peking Union Medical College Hospital

    lead OTHER

Principal Investigators

  • Junling Zhuang, MD · Peking UMCH

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-26
Primary Completion
2024-07-26
Completion
2024-07-26
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04989140 on ClinicalTrials.gov